TaxuCardium Pharmaceuticals Group Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced loss from operations of $956,325 compared to $1,856,351 for the same period a year ago. Net loss from continuing operations was $984,925 compared to $1,856,351 for the same period a year ago. Net loss was $984,925 compared to $2,117,548 for the same period a year ago. Net loss applicable to common stockholders was $984,925 compared to $2,350,559 for the same period a year ago. Net loss per share from continued operations, basic and diluted was $0.09 compared to $0.33 for the same period a year ago. Net loss per share, basic and diluted was $0.09 compared to $0.37 for the same period a year ago. Non-GAAP net loss was $983,807 compared to $2,117,548 for the same period a year ago. Non-GAAP net loss per common share, basic and diluted was $0.09 compared to $0.33 for the same period a year ago.

For the six months, the company announced loss from operations of $2,375,747 compared to $3,831,604 for the same period a year ago. Net loss from continuing operations was $2,423,414 compared to $3,832,158 for the same period a year ago. Net loss was $2,423,414 compared to $4,379,903 for the same period a year ago. Net loss applicable to common stockholders was $2,423,414 compared to $4,612,914 for the same period a year ago. Net loss per share from continued operations, basic and diluted was $0.24 compared to $0.68 for the same period a year ago. Net loss per share, basic and diluted was $0.24 compared to $0.72 for the same period a year ago. Non-GAAP net loss was $1,916,131 compared to $4,339,153 for the same period a year ago. Non-GAAP net loss per common share, basic and diluted was $0.19 compared to $0.68 for the same period a year ago.